ArchiveNovember 2011

Team G

If you want another opertunity to see & meet members of Team G.The folks at Shift MS offered up Dr M&M on top tips for excersiceNow you can see Dr M&M give some Answers to the Questions PostedIf you don’t want to see, don’t press the links

Blog News: Silencing the Critics

Whilst trying to think about how to take the blog forward You wrote: “Why not cut the comments?“ Although this would limit time spent responding to posts and limit the tongue lashings that Prof G often gets, we felt that it does give you an oppertunity to ask questions. In addition they give us ideas for posts and your comments are often some of the most enligthening features, so we...

CCSVI trending downwards

CCSVI as monitored with Google Trends “The Google trend data on CCSVI continues to show a downward trend.  The majority of hits are still from Canada, Italy and Serbia; a very interesting regional social phenomenon.” “When the dust settles on CCSVI it will be worth a detailed analysis to see if we can learn any lessons to prevent this from happening...

Natalizumab PML Update – 181 cases as of 1st Nov

Status of MS’ers with PML as of 1st November, 2011:  38 patients have died (21%); most of the deaths have occurred within approximately 2 months after PML diagnosis  143 patients are alive (79%), it is too early to draw conclusions about the outcomes of patients who develop PML while on natalizumab treatment. The following is the risk profiling algorithm with updated risks:...

Basic Science: More clues for targets for remyelination

Chung AY et al. Microarray Screening for Genes Involved in Oligodendrocyte Differentiation in the Zebrafish CNS. Exp Neurobiol 2011 ;20:85-91. Within the vertebrate nervous system, myelination is required for the normal function of neurons (nerves) by facilitating the rapid conduction of action potentials (nerve impulses) along axons. Oligodendrocytes (myelin-forming cells) are glial cells which...

MS Research Day Tomorrow Calendar

It’s that time of year and soon January 2012 will be upon us. To help you rembember our MS Research Day on the 28th January, in Westminister Central London. You are all invited and it’s free…now that’s what I call a Christmas present. As treat I am doing Calender Mouse and will be shedding my usual white coat to put on some new outfits for our advent calendar that starts...

Research:Iron deposition elevated in MS

Habib CA et al. Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis versus Healthy Controls. AJNR Am J Neuroradiol. 2011 Nov [Epub] BACKGROUND AND PURPOSE: It is well known that patients with MS tend to have abnormal iron deposition in and around the MS plaques in the brain. In this study, we quantify iron content in patients with MS and healthy...

Brain atrophy in benign MS

Another post in response to the question about benign MS. Gauthier et al. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb;66(2):234-7. BACKGROUND: Benign MS is defined by minimal or no disability after many years of observation, therefore a less degenerative disease process is suspected to be present in this subset of patients. OBJECTIVE: To...

Natalizumab in SPMS

In response to one of yesterday’s comments: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS (ASCEND in SPMS) Eligibility Ages Eligible for Study: 18 Years to 58 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No CriteriaMajor Inclusion Criteria: Ability to understand the purpose and risks of the study and provide...

Survey results: Big Pharma

“I don’t find this result surprising given the current reputational issues Big Pharma have with the general public.However, I disagree with these results. If it wasn’t for Big Pharma we wouldn’t have DMTs for MS or the exciting pipeline that currently exists.”“MS’ers may be surprised but there are currently two PPMS and one SPMS trial recruiting sponsored...

Translate

Categories

Recent Posts

Recent Comments

Archives